Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ENGN
stocks logo

ENGN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.578
+70.1%
--
--
-0.637
+32.64%
--
--
-0.648
+27.12%
Estimates Revision
The market is revising No Change the revenue expectations for enGene Holdings Inc. (ENGN) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 58.69%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+58.69%
In Past 3 Month
Wall Street analysts forecast ENGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENGN is 22.56 USD with a low forecast of 10.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast ENGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENGN is 22.56 USD with a low forecast of 10.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.220
sliders
Low
10.00
Averages
22.56
High
33.00
Current: 8.220
sliders
Low
10.00
Averages
22.56
High
33.00
UBS
Neutral
maintain
$4 -> $10
2025-11-12
Reason
UBS
Price Target
$4 -> $10
2025-11-12
maintain
Neutral
Reason
UBS raised the firm's price target on enGene (ENGN) to $10 from $4 and keeps a Neutral rating on the shares. EnGene reported updated Phase 2 LEGEND trial data for detalimogene in high-risk BCG-unresponsive non-muscle invasive bladder cancer, showing a 63% anytime complete response rate and 62% six-month CR under the amended protocol, an improvement from prior results but below competitors CG Oncology (CGON) and Johnson & Johnson (JNJ), the analyst tells investors in a research note. While the results confirm deta's activity, limited near-term catalysts and a later market entry contribute to a Neutral outlook.
Oppenheimer
Oppenheimer
Outperform
maintain
$30 -> $33
2025-11-12
Reason
Oppenheimer
Oppenheimer
Price Target
$30 -> $33
2025-11-12
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on enGene to $33 from $30 and keeps an Outperform rating on the shares. The firm believes the reveal from the pivotal LEGEND trial in high-risk NMIBC is not only impressive in its own right - highlighted by detalimogene's 62% 6-month complete response rate - but also addresses the market's skepticism following last September's initial showing, which preceded changes that brought the trial's design closer to current standards for this indication.
Morgan Stanley
Overweight
maintain
$18 -> $19
2025-11-12
Reason
Morgan Stanley
Price Target
$18 -> $19
2025-11-12
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on enGene to $19 from $18 and keeps an Overweight rating on the shares after the company provided updated data from the pivotal cohort of its Phase 2 LEGEND trial, investigating its non-viral gene therapy detalimogene in Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer patients. Detalimogene's profile appears competitive with other NMIBC agents and 6-month CR was the "standout measure," says the analyst, who sees the update improving detalimogene's product profile.
Citizens JMP
Silvan Tuerkcan
Outperform
maintain
$18 -> $21
2025-11-12
Reason
Citizens JMP
Silvan Tuerkcan
Price Target
$18 -> $21
2025-11-12
maintain
Outperform
Reason
Citizens JMP analyst Silvan Tuerkcan raised the firm's price target on enGene to $21 from $18 and keeps an Outperform rating on the shares. Citizens was impressed by the speed of enrollment in enGene's LEGEND trial and the substantially higher complete response rate following protocol amendments that harmonized LEGEND with other newer non-muscle invasive bladder cancer assets, the analyst tells investors in a research note. EnGene has demonstrated that detalimogene is comparable to best-in-class assets on six-month CR, and the update puts detalimogene in the range of the most efficacious therapies, removing the efficacy barrier, the firm says.
Raymond James
Outperform -> Strong Buy
upgrade
$23 -> $27
2025-11-11
Reason
Raymond James
Price Target
$23 -> $27
2025-11-11
upgrade
Outperform -> Strong Buy
Reason
Raymond James upgraded enGene to Strong Buy from Outperform with a price target of $27, up from $23.
Raymond James
Sean McCutcheon
Outperform -> Strong Buy
upgrade
$23 -> $27
2025-11-11
Reason
Raymond James
Sean McCutcheon
Price Target
$23 -> $27
2025-11-11
upgrade
Outperform -> Strong Buy
Reason
Raymond James analyst Sean McCutcheon upgraded enGene to Strong Buy from Outperform with a price target of $27, up from $23, after the company disclosed an interim update from the pivotal cohort in their Phase 2 LEGEND study, comprised of patients with high-risk BCG unresponsive non-muscle invasive bladder cancer treated with detalimogene. The company included more patients in the analysis than anticipated, which the firm sees having a positive read on the rate of enrollment and on execution, notes the analyst, who did not modify revenue projections but cites "the substantial market opportunity" within NMIBC, particularly at community urology clinics, with efficacy approaching cretostimogene.
See All Ratings

Valuation Metrics

The current forward P/E ratio for enGene Holdings Inc (ENGN.O) is -3.27, compared to its 5-year average forward P/E of -3.03. For a more detailed relative valuation and DCF analysis to assess enGene Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.03
Current PE
-3.27
Overvalued PE
-0.08
Undervalued PE
-5.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.06
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.30
Undervalued EV/EBITDA
-5.43

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ENGN News & Events

Events Timeline

(ET)
2025-12-02
07:50:00
enGene's Detalimogene Voraplasmid Selected for FDA Pilot Program
select
2025-11-13 (ET)
2025-11-13
06:14:19
enGene Prices 12.559 Million Share Spot Secondary Offering at $8.50
select
2025-11-12 (ET)
2025-11-12
16:06:54
enGene Announces Offering of Common Shares, Amount Not Disclosed
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-02Newsfilter
enGene Selected for FDA CDRP Program to Accelerate Drug Development
  • FDA Program Participation: enGene's detalimogene voraplasmid has been selected for the FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, which aims to expedite clinical development timelines and provide patients with earlier access to therapies.
  • Manufacturing Capacity Enhancement: Detalimogene has already been scaled to commercial manufacturing levels, and participation in the CDRP is expected to facilitate additional FDA interactions to ensure CMC readiness for a Biologics License Application (BLA) submission in the second half of 2026.
  • Clinical Trial Progress: In the pivotal cohort of the LEGEND trial, detalimogene demonstrated a 62% six-month complete response rate among 125 high-risk NMIBC patients, indicating its potential effectiveness for BCG-unresponsive patients.
  • Strategic Implications: This FDA recognition not only bolsters enGene's confidence in detalimogene's potential but also underscores the company's commitment to strong manufacturing practices, aiming to address the urgent medical needs of high-risk NMIBC patients.
[object Object]
Preview
4.0
11-13Benzinga
Oppenheimer Affirms Outperform Rating for enGene Holdings and Increases Price Target to $33

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.

  • Market Success: Traders utilize Benzinga Pro's resources to gain a competitive edge and improve their chances of winning in the markets daily.

[object Object]
Preview
9.0
11-12TipRanks
Reasons Behind the Surge in enGene Holdings Stock Today

  • Stock Surge: enGene Holdings (ENGN) stock rose over 65% after promising preliminary results from its Phase 2 LEGEND trial for bladder cancer gene therapy, detalimogene voraplasmid.

  • Trial Results: The trial showed a 62% complete response rate at six months for patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer, with a favorable safety profile.

  • FDA Approval Plans: enGene plans to submit its therapy for FDA approval in the second half of 2026, potentially enhancing its position in bladder cancer treatment.

  • Analyst Upgrades: Raymond James analyst Sean McCutcheon upgraded ENGN to a Buy rating with a price target of $27, citing strong trial enrollment and execution, and a Strong Buy consensus rating on Wall Street.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is enGene Holdings Inc (ENGN) stock price today?

The current price of ENGN is 8.22 USD — it has increased 2.75 % in the last trading day.

arrow icon

What is enGene Holdings Inc (ENGN)'s business?

enGene Holdings Inc. is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II study, which includes a cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. The Company is developing non-viral genetic medicines based on its DDX gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

arrow icon

What is the price predicton of ENGN Stock?

Wall Street analysts forecast ENGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENGN is 22.56 USD with a low forecast of 10.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is enGene Holdings Inc (ENGN)'s revenue for the last quarter?

enGene Holdings Inc revenue for the last quarter amounts to -29.95M USD, increased 78.69 % YoY.

arrow icon

What is enGene Holdings Inc (ENGN)'s earnings per share (EPS) for the last quarter?

enGene Holdings Inc. EPS for the last quarter amounts to -26338000.00 USD, increased 266.67 % YoY.

arrow icon

What changes have occurred in the market's expectations for enGene Holdings Inc (ENGN)'s fundamentals?

The market is revising No Change the revenue expectations for enGene Holdings Inc. (ENGN) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 58.69%.
arrow icon

How many employees does enGene Holdings Inc (ENGN). have?

enGene Holdings Inc (ENGN) has 56 emplpoyees as of December 05 2025.

arrow icon

What is enGene Holdings Inc (ENGN) market cap?

Today ENGN has the market capitalization of 532.12M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free